These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 38650924)

  • 1. Macrophages: plastic participants in the diagnosis and treatment of head and neck squamous cell carcinoma.
    Lin C; Chu Y; Zheng Y; Gu S; Hu Y; He J; Shen Z
    Front Immunol; 2024; 15():1337129. PubMed ID: 38650924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor immune microenvironment in head and neck cancers.
    Chen SMY; Krinsky AL; Woolaver RA; Wang X; Chen Z; Wang JH
    Mol Carcinog; 2020 Jul; 59(7):766-774. PubMed ID: 32017286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Machine learning developed a macrophage signature for predicting prognosis, immune infiltration and immunotherapy features in head and neck squamous cell carcinoma.
    Wang Y; Mou YK; Liu WC; Wang HR; Song XY; Yang T; Ren C; Song XC
    Sci Rep; 2024 Aug; 14(1):19538. PubMed ID: 39174693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for Head and Neck Cancer.
    Sim F; Leidner R; Bell RB
    Hematol Oncol Clin North Am; 2019 Apr; 33(2):301-321. PubMed ID: 30833002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
    Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
    Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma.
    Seliger B; Massa C; Yang B; Bethmann D; Kappler M; Eckert AW; Wickenhauser C
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of macrophages in head and neck squamous cell carcinoma and development of MRG-based risk signature.
    Liu L; Liu Q
    Sci Rep; 2024 Apr; 14(1):9914. PubMed ID: 38688945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.
    Farlow JL; Brenner JC; Lei YL; Chinn SB
    Oral Oncol; 2021 Sep; 120():105420. PubMed ID: 34218062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.
    Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG
    J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head and neck squamous cell carcinoma cell lines have an immunomodulatory effect on macrophages independent of hypoxia and toll-like receptor 9.
    Ishizu T; Eichin D; Padzik A; Tuominen S; Grénman R; Salmi M; Grönroos TJ; Tuomela JM
    BMC Cancer; 2021 Sep; 21(1):990. PubMed ID: 34479492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.
    Miyauchi S; Kim SS; Pang J; Gold KA; Gutkind JS; Califano JA; Mell LK; Cohen EEW; Sharabi AB
    Clin Cancer Res; 2019 Jul; 25(14):4211-4223. PubMed ID: 30814108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
    Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
    Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune escape mechanisms in head and neck squamous cell carcinoma and implication for new immunotherapy approach.
    Merlano MC; Denaro N; Garrone O
    Curr Opin Oncol; 2020 May; 32(3):203-209. PubMed ID: 32195680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment.
    Ruffin AT; Li H; Vujanovic L; Zandberg DP; Ferris RL; Bruno TC
    Nat Rev Cancer; 2023 Mar; 23(3):173-188. PubMed ID: 36456755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-derived extracellular vesicles in the immune microenvironment of head and neck squamous cell carcinoma: Foe or future?
    Xu Q; Li X
    J Stomatol Oral Maxillofac Surg; 2024 Sep; 125(4):101738. PubMed ID: 38097013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
    J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive investigation into the influence of glycosylation on head and neck squamous cell carcinoma and development of a prognostic model for risk assessment and anticipating immunotherapy.
    Ma H; Xiong L; Zhao B; Hahan Z; Wei M; Shi H; Yang S; Ren Q
    Front Immunol; 2024; 15():1364082. PubMed ID: 38562924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and Differentiation of the Tumor Microenvironment (TME) of Orthotopic and Subcutaneously Grown Head and Neck Squamous Cell Carcinoma (HNSCC) in Immunocompetent Mice.
    Brand M; Laban S; Theodoraki MN; Doescher J; Hoffmann TK; Schuler PJ; Brunner C
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Subtypes Based on Cell Differentiation Trajectories in Head and Neck Squamous Cell Carcinoma: Differential Prognosis and Immunotherapeutic Responses.
    Huang ZD; Liu ZZ; Liu YY; Fu YC; Lin LL; Hu C; Gu HY; Wei RX
    Front Immunol; 2021; 12():791621. PubMed ID: 35003112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of EphB4-Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers.
    Bhatia S; Oweida A; Lennon S; Darragh LB; Milner D; Phan AV; Mueller AC; Van Court B; Raben D; Serkova NJ; Wang XJ; Jimeno A; Clambey ET; Pasquale EB; Karam SD
    Cancer Res; 2019 May; 79(10):2722-2735. PubMed ID: 30894369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.